Claim
Multiple large-scale studies, including a 2025 multisite cohort across six population-based databases and a 2024 Scandinavian cohort study with 3.9 years mean follow-up, found no evidence that GLP-1 receptor agonist use is associated with increased thyroid cancer risk compared to DPP-4 inhibitor use.
Evidence (2)
GLP-1 Receptor Agonists and Risk of Thyroid Cancer: An International Multisite Cohort Study
Six-country multisite cohort study found no evidence of increased thyroid cancer risk with GLP-1RA use over 1.8-3.0 year follow-up.
https://pubmed.ncbi.nlm.nih.gov/39772758/
Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study
Large Scandinavian cohort found no substantial increased thyroid cancer risk over 3.9 years mean follow-up.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11004669/
Embed this claim
<iframe src="https://www.isonomia.app/embed/claim/99e0dceefeaee5dcf214a4d9d974be0b19020e8f8e0b8bcd851fb36eabe50a6e" width="600" height="280" frameborder="0" style="border: 1px solid #e5e7eb; border-radius: 8px;" title="Isonomia Claim" loading="lazy" ></iframe>
Copy and paste into any website or forum that supports HTML.
Respond to this claim on Isonomia
Build or challenge arguments with structured reasoning in the Digital Agora.